The BZLF1 homolog of an Epstein-Barr-related γ-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques

Journal of Immunology

Volumn 176, Issue 6, 2006, Pages 3391-3401

  Fogg, Mark H ^a   Garry, Deirdre ^a   Awad, Amany ^a   Wang, Fred ^a   Kaur, Amitinder ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RHBZLF1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HERPES VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION CONTROL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RHESUS MONKEY; SEQUENCE HOMOLOGY; VIRUS INFECTION; VIRUS REPLICATION;

EID: 33644842473     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.6.3391     Document Type: Article

References (36)

1. Rickinson, A., and E. Kieff. 2001. Epstein-Barr virus. In Fields Virology, Vol. 2. D. M. Knipe and P. M. Howley, eds. Lippincott Williams and Wilkins, Philadelphia, pp. 2575-2627.
2. Rooney, C. M., C. A, Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
3. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176: 157-168.
4. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, T. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176: 169-176.
5. Gavioli, R., P. O. De Campos-Lima, M. G. Kurilla, E. Kieff, G. Klein, and M. G. Masucci. 1992. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc. Natl. Acad. Sci. USA 89: 5862-5866.
6. Bogedain, C., H. Wolf, S. Modrow, G. Stuber, and W. Jilg. 1995. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J. Virol. 69: 4872-4879.
7. Elliott, S. L., S. J. Pye, C. Schmidt, S. M. Cross, S. L. Silins, and I. S. Misko. 1997. Dominant cytotoxic T lymphocyte response to the immediate-early transactivator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. J. Infect. Dis. 176: 1068-1072.
8. Saulquin, X., C. Ibisch, M. A. Peyrat, E. Scotet, M. Hourmant, H. Vie, M. Bonneville, and E. Houssaint. 2000. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30: 2531-2539.
9. Steven, N. M., N. E. Annels, A. Kumar, A. M. Leese, M. G. Kurilla, and A. B. Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185: 1605-1617.
10. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J. Exp. Med. 201: 349-360.
11. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162: 1827-1835.
12. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195: 893-905.
13. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187: 1395-1402.
14. + T cell responses after natural primary infection of humans with Epstein-Barr virus. Viral Immunol. 16: 3-16.
15. Rivailler, P., H. Jiang, Y. G. Cho, C. Quink, and F. Wang. 2002. Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J. Virol. 76: 421-426.
16. Rangan, S. R., L. N. Martin, B. E. Bozelka, N. Wang, and B. J. Gormus. 1986. Epstein-Barr virus-related herpesvirus from a rhesus monkey (Macaca mulatta) with malignant lymphoma. Int. J. Cancer 38: 425-432.
17. Rao, P., H. Jiang, and F. Wang. 2000. Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections. J. Clin. Microbiol. 38: 3219-3225.
18. Rivailler, P., A. Carville, A. Kaur, P. Rao, C. Quink, J. L. Kutok, S. Westmoreland, S. Klumpp, M. Simon, J. C. Aster, and F. Wang. 2004. Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: an animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 104: 1482-1489.
19. Moghaddam, A., M. Rosenzweig, D. Lee-Parritz, B. Annis, R. P. Johnson, and F. Wang. 1997. An animal model for acute and persistent Epstein-Barr virus infection. Science 276: 2030-2033.
20. + T-cell response to an Epstein-Barr virus-related γ-herpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J. Virol. 79: 12681-12691.
21. Anonymous. 1996. The Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and use of Laboratory Animals. National Institutes of Health, Washington, DC, pp. 86-123.
22. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, and D. I. Watkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50: 657-661.
23. Lobashevsky, A. L., and J. M. Thomas. 2000. Six mamu-A locus alleles defined by a polymerase chain reaction sequence specific primer method. Hum. Immunol. 61: 1013-1020.
24. Muhl, T., M. Krawczak, P. Ten Haaft, G. Hunsmann, and U. Sauermann. 2002. MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J. Immunol. 169: 3438-3446.
25. Mazzara, G. P., A. Destree, and A. Mahr. 1993. Generation and analysis of vaccinia virus recombinants. J. Immunol. 217: 557-581.
26. Rabin, H., R. H. Neubauer, R. F. Hopkins III and M. Nonoyama. 1978. Further characterization of a herpesvirus-positive orangutan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses. Int. J. Cancer 21: 762-767.
27. + T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J. Virol. 76: 3646-3658.
28. Houssaint, E., X. Saulquin, E. Scotet, and M. Bonneville. 2001. Immunodominant CD8 T cell response to Epstein-Barr virus. Biomed. Pharmacother. 55: 373-380.
29. Shimizu, Y., D. E. Geraghty, B. H. Koller, H. T. Orr, and R. DeMars. 1988. Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 85: 227-231.
30. Sidney, J., J. L. Dzuris, M. J. Newman, R. P. Johnson, A. Kaur, C. M. Walker, E. Appella, B. Mothe, D. I. Watkins, and A. Sette. 2000. Definition of the Mamu A*01 peptide binding specificity: application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins. J. Immunol. 165: 6387-6399.
31. Hickman-Miller, H. D., W. Bardet, A. Gilb, A. D. Luis, K. W. Jackson, D. I. Watkins, and W. H. Hildebrand. 2005. Rhesus macaque MHC class I molecules present HLA-B-like peptides. J. Immunol. 175: 367-375.
32. Woodberry, T., T. J. Suscovich, L. M. Henry, J. K. Davis, N. Frahm, B. D. Walker, D. T. Scadden, F. Wang, and C. Brander. 2005. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis. 192: 1513-1524.
33. Silins, S. L., M. A. Sherritt, J. M. Silleri, S. M. Cross, S. L. Elliott, M. Bharadwaj, T. T. Le, L. E. Morrison, R. Khanna, D. J. Moss, et al. 2001. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 98: 3739-3744.
34. Scotet, E., J. David-Ameline, M. A. Peyrat, A. Moreau-Aubry, D. Pinczon, A. Lim, J. Even, O. Semana, J. M. Berthelot, R. Breathnach, et al. 1996. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J. Exp. Med. 184: 1791-1800.
35. Redchenko, I. V., and A. B. Rickinson. 1999. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J. Virol. 73: 334-342.
36. Hicks, M. R., S. S. Al-Mehairi, and A. J. Sinclair. 2003. The zipper region of Epstein-Barr virus bZIP transcription factor Zta is necessary but not sufficient to direct DNA binding. J. Virol. 77: 8173-8177.